1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Zhejiang Starry Pharmaceutical Co., Ltd

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

1997

Location

Zhejiang China

Primary Industry

Pharmaceuticals

About

Established in 1997 and based in Xianjju, China, Zhejiang Starry Pharmaceutical Co., Ltd operates as a contrast agent and API developer. The company's product iohexol products passed GMP certification for the first time and obtained GMP certificate in 2005. The company listed on the Shanghai Stock Exchange in March 2013 and the stock code is 603520. The company acquired Zhejiang Taizhou Haishen Pharmaceutical Co., Ltd in 2018. Jiangxi Starry Pharmaceutical Co.,Ltd. and Shanghai Starry Pharmaceutical Co.,Ltd. subsidiary of the company. The company provides generic contrast agent products. The business of the company includes R & D, production and sales of X-CT non-ionic contrast agent series and quinolone series APIs and intermediates. The company's product includes contrast agent series and fluoroquinolone series. Contrast agent series includes iohexol, iodomeprazole and gadolinium besmeglumine. Fluoroquinolone series includes levofloxacin, levofloxacin hydrochloride and levofloxacin epoxide.
Current Investors
ICBC Credit Suisse Asset Management, GF Fund Management, Shenzhen Qianhai Guotai Funds

Request a demo to show more

Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.starrypharm.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.